{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-029340","form_type":"8-K","ticker":"AQST","cik":"0001398733","company_name":"Aquestive Therapeutics, Inc.","filed_at":"2024-06-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.239609+00:00","generated_at":"2026-06-01T02:46:06.756215+00:00","sec_items":["5.07"],"event_type":"other","sentiment":"neutral","materiality_score":0.04,"calibrated_materiality_score":0.04,"confidence":"high","headline":"Aquestive Therapeutics reports 2024 annual meeting voting results","bullets":["Elected Santo J. Costa, Julie Krop, and Marco Taglietti as Class III directors with 24.9M, 21.6M, and 24.9M votes for.","Non-binding advisory vote on executive compensation approved: 23.6M for, 1.6M against.","Advisory vote frequency set at one year (24.6M for).","Ratified KPMG as independent auditor for FY 2024: 50.7M for, 0.9M against."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-029340","json":"https://secwatch.observer/filing/0001628280-24-029340.json","markdown":"https://secwatch.observer/filing/0001628280-24-029340.md","text":"https://secwatch.observer/filing/0001628280-24-029340.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1398733/000162828024029340/0001628280-24-029340-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1398733/000162828024029340/aqst-20240620.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T02:46:06.756215+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}